Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome
JAMA Neurology · 01.10.2024 · 81 (10) · 1066
DOI: 10.1001/jamaneurol.2024.2579 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Neurology, erschienen am 01.10.2024. Verfasst von Lei Liu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Hauptthemen laut MEDLINE: Down Syndrome, Brain, Plaque, Amyloid. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS.
Abstract (Originalsprache)
Importance Anti-β-amyloid immunotherapy using lecanemab is becoming increasingly available to patients with Alzheimer disease (AD). Individuals with Down syndrome (DS) develop AD neuropathology by age 40 years, representing a significant cohort of genetically determined AD.
Objective
To investigate the binding properties of lecanemab in the brains of people with DS, in anticipation of their inclusion in clinical trials or access to antiamyloid immunotherapies. Design, Setting, Participants The study included cases of postmortem brain tissue analysis from 15 individuals with DS aged 43 to 68 years that were acquired from Alzheimer Disease research centers at the University of California, Irvine and the University of Kentucky from 2008 to 2021. Data were analyzed from August 2023 through May 2024. Exposure The binding properties of lecanemab were assessed in brain tissue. Main Outcome The primary outcome was the extent of lecanemab binding to amyloid plaques and brain blood vessels.
Results
Tissue from 15 people (8 were female [53%]) with DS ranging in age from 43 to 68 (mean, 56.6) years were included in the study. Lecanemab-labeled amyloid plaques appeared in all 15 DS cases studied, indicating potential target engagement. However, extensive binding of lecanemab to brain blood vessels in DS was observed, raising significant safety concerns. These findings underscore the necessity for clinical trials of lecanemab in people with DS to evaluate both safety and efficacy, particularly in individuals older than 43 years. Conclusions and Relevance These findings suggest significant binding of lecanemab to cerebral amyloid angiopathy in DS. Lecanemab should be rigorously tested in clinical trials for AD in the DS population to determine its safety and efficacy, especially in those older than 43 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
- Department of Pathology and Laboratory Medicine, Department of Neurology, University of California, Irvine.
- Taub Institute for Research on Alzheimer's Disease and the Aging Brain and Department of Neurology, Columbia University, New York.
- Indiana University School of Medicine, Indianapolis.
- Department of Neurology, Sanders-Brown Center on Aging, University of Kentucky, Lexington.
- Massachusetts General Hospital, Harvard Medical School, Boston.
Förderung
- NIA NIH HHS
Zitieren
APA
Liu, L., Saba, A., Pascual, J. R., Miller, M. B., Hennessey, E. L., Lott, I. T., Brickman, A. M., Wilcock, D. M., Harp, J. P., Schmitt, F. A., Selkoe, D. J., Chhatwal, J. P., & Head, E. (2024). Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome. JAMA Neurology, 81(10), 1066. https://doi.org/10.1001/jamaneurol.2024.2579
Vancouver
Liu L, Saba A, Pascual JR, Miller MB, Hennessey EL, Lott IT, et al. Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome. JAMA Neurology. 2024;81(10):1066. doi:10.1001/jamaneurol.2024.2579
BibTeX
@article{Liu2024,
author = {Liu, Lei and Saba, Adriana and Pascual, Jesse R and Miller, Michael B and Hennessey, Elizabeth L and Lott, Ira T and Brickman, Adam M and Wilcock, Donna M and Harp, Jordan P and Schmitt, Frederick A and Selkoe, Dennis J and Chhatwal, Jasmeer P and Head, Elizabeth},
title = {Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome},
journal = {JAMA Neurology},
year = {2024},
volume = {81},
number = {10},
pages = {1066},
doi = {10.1001/jamaneurol.2024.2579}
}
EUVIMED